PT  - JOURNAL ARTICLE
AU  - RIIKKA-LIISA VUORINEN
AU  - NIINA PAUNU
AU  - TAINA TURPEENNIEMI-HUJANEN
AU  - TAINA REUNAMO
AU  - ANTTI JEKUNEN
AU  - VESA KATAJA
AU  - HARRI SINTONEN
AU  - TIMO PURMONEN
AU  - PIRKKO-LIISA KELLOKUMPU-LEHTINEN
TI  - Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
AID  - 10.21873/anticanres.13749
DP  - 2019 Oct 01
TA  - Anticancer Research
PG  - 5559--5564
VI  - 39
IP  - 10
4099  - http://ar.iiarjournals.org/content/39/10/5559.short
4100  - http://ar.iiarjournals.org/content/39/10/5559.full
SO  - Anticancer Res2019 Oct 01; 39
AB  - Background/Aim: Tyrosine kinase inhibitors are important in the treatment of metastatic renal cell cancer (mRCC). The aim of the study was to evaluate the costs and effects of sunitinib in mRCC. Patients and Methods: A total of 81 mRCC patients who received first-line sunitinib therapy between 2010 and 2014 were recruited. Drug doses, laboratory and imaging studies, outpatient visits and inpatient stays were recorded. Health-related quality of life (HRQoL) was measured (15D- and EQ-5D – 3L questionnaires). Results: The cost of sunitinib (mean 22,268 €/patient range 274 € to 105,121 €) covered 73% of the total costs during the treatment period. The total treatment cost was 30,530 €/patient (range=1,661-111,516 €). The median overall survival was 17.9 months. HRQoL decreased during treatment. Conclusion: The main cost during sunitinib treatment of mRCC was the drug itself (73% of the total costs). Drug costs and HRQoL should be considered when choosing treatment for mRCC.